You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company is also working on a new Saphyr system that will have 14 times higher throughput than the current one, which can analyze 5,000 human genomes per year.
Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.
NeoGenomics will offer Trapelo's clinical decision support system to providers, payors, and labs to aid precision oncology across all healthcare settings.
The firm used the proceeds to repay outstanding borrowings of $25.9 million under its existing loan with Innovatus Life Sciences Lending Fund.
The partners believe the platform, which captures high resolution images of CTCs and clusters, has potential applications in early cancer detection and disease monitoring.
CellMax also completed a Series C financing round to speed up development of itsFirstSight liquid biopsy test to detect colorectal cancer and precancer polyps.
The firm said it will begin running its urine-based test immediately in its clinical laboratory in Munich and make it available throughout Europe.
The global distribution deal with Epredia follows Paige's closing of a $125 million round of Series C financing earlier this year.
The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.
The firms plan to build a workflow for CTC isolation directly from a patient's bloodstream for single-cell downstream molecular analysis such as sequencing, genotyping, or digital PCR.
Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.
For the three months ended Dec. 31, the Boulder, Colorado-based firm reported revenues of $27.0 million compared to $8.3 million in 2019.
Still early in its clinical testing operations, the company shrank its net loss to $6.3 million or $.09 per share during the quarter.
Roche Diagnostics CEO Thomas Schinecker said the infrastructure put in place due to the pandemic will allow for more diagnostic testing globally.
The partners will assess Stella's assay by quantifying proto-oncogenes in Barrett's esophagus tissue that have progressed to cancer, and those that have not.
The firm said it has developed a POC test that uses a biomarker for HPV16, which is responsible for more than 90 percent of all HPV-related head and neck tumors.
The deal to create a comprehensive genomic profiling test for Illumina's NextSeq 550Dx comes months after the instrument received regulatory approval in China.
NeoGenomics will use its gene fusion panels to identify patients with solid tumors and an NRG1 fusion who might qualify for Elevation's Phase II CRESTONE study.
The lab will perform DNA and RNA sequencing as well as well as liquid biopsy analyses to advance precision oncology in New Jersey and the East Coast.
BioMark Diagnostics has been collaborating on the test with the Metabolomics Innovation Centre at the University of Alberta since early 2015.